2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
8
Neoplasms
4
Neoplasm Metastasis
4
Endometrial Neoplasms
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostatic Diseases
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Male Urogenital Diseases
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Genital Diseases, Male
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasm Malignant Female
1
Advanced Cancer
1
Interventions
Cisplatin
55
Carboplatin
49
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
Sunitinib
10
Platinum
10
130-nm albumin-bound paclitaxel
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
gedatolisib
×
Clear all
NCT02920450
2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2
Terminated
3 enrolled
8 charts